EVP-6124 as a treatment to improve mental function in Schizophrenia

• Research type

  Research Study

• Full title

  A Randomized, Double-blind, Placebo-controlled, Parallel, 26 Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

• IRAS ID

  116726

• Contact name

  Sukhi Shergill

• Contact email

  sukhi.shergill@kcl.ac.uk

• Sponsor organisation

  Forum Pharmaceuticals, Inc.

• Eudract number

  2012-003209-92

• Clinicaltrials.gov Identifier

  NCT01716975

• Research summary

  Schizophrenia comes with a wide range of symptoms including moderate to severe decreases in a patient’s cognitive ability (A group of mental functions like attention, problem solving, memory and language)
  There are currently no treatments available to treat this decrease in cognitive ability however the objective of this study is to assess the safety and efficacy of two doses of EVP-6124 (1mg and 2mg) taken once daily as an pro-cognitive treatment when taken in conjunction with antipsychotic therapy.

• REC name

  London - Chelsea Research Ethics Committee

• REC reference

  13/LO/0702

• Date of REC Opinion

  22 Oct 2013

• REC opinion

  Further Information Favourable Opinion